TekiTrust Tests to Determine the Level of SARS-COV-2/COVID-19 Neutralizing Antibodies in the Blood
Study Details
Study Description
Brief Summary
The purpose of this study is to determine if the TekiTrust Enzyme-Linked Immunosorbent Assay (ELISA) Kit and TekiTrust Rapid Test can accurately determine the amount of antibodies to fight the COVID-19 virus in sampled blood compared to the standard Plaque Reduction Neutralization Test (PRNT) test.
When a person has COVID-19 they develop antibodies to the virus which are contained in their blood stream. After a certain period, the number of antibodies to fight (neutralize) the virus begin to decrease. One common way to measure the amount of antibodies in the blood is to use a test called the PRNT. The focus of this study is to compare the ability of the TekiTrust ELISA Kit and the TekiTrust Rapid Test with the PRNT to determine if these tests can measure the antibodies equally well.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
Participants who have been previously diagnosed with COVID-19 within the past 3 months through any FDA emergency use approved (EUA) assay test will eligible for inclusion in the study. A blood and fingerstick sample will be obtained from the participant and for subjects with a positive test and symptom onset of less than 30 days a repeat RT-PCR nasal pharyngeal swab sample will be taken. The fingerstick sample will be used onsite by qualified site staff to test the TekiTrust SARS-CoV-2 Neutralizing Antibody Detection Rapid Test. These results will be compared to the whole blood sample sent to the lab which will be analysed for SARS CoV-2 neutralizing antibodies using the TekiTrust SARS-CoV-2 Neutralizing Antibody Detection ELISA Kit and the comparator Plaque Reduction Neutralization Test (PRNT) test.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Current COVID-19 symptoms or SARS-CoV-2 in the last 30 days with a positive RT-PCR test 75 subjects will be enrolled who were diagnosed as SARS-CoV-2 with a positive RT-PCR nasal pharangeal test or are suspected of having a COVID-19 infection with symptom onset in the last 30 days. (Symptom onset 0-30 days) This group of subjects will receive: a fingerstick blood sample for a rapid test neutralizing antibody test to be done in the office with the TekiTrust SARS-CoV-2 Neutralizing Antibody Detection Rapid Test a blood draw which will be sent to the lab for neutralizing antibody testing with the TekiTrust SARS-CoV-2 Nuetralizing Antibody Detection ELISA Kit and the standard Plaque Reduction Neutralization Test (PRNT) a nasal-pharangeal RT-PCR test |
|
| Diagnosed with SARS-CoV-2 (COVID-19) in the past 3 months with a positive RT-PCR test 30 subjects will be enrolled who have been diagnosed with COVID-19 in the past 3 months and had a prior positive RT-PCR nasal pharangeal test. (Symptom onsent 31-90 days) This group of subjects will receive: a fingerstick blood sample for a rapid test neutralizing antibody test to be done in the office with the TekiTrust SARS-CoV-2 Neutralizing Antibody Detection Rapid Test a blood draw which will be sent to the lab for neutralizing antibody testing with the TekiTrust SARS-CoV-2 Nuetralizing Antibody Detection ELISA Kit and the standard Plaque Reduction Neutralization Test (PRNT) |
Outcome Measures
Primary Outcome Measures
- Clinical agreement between TekiTrust SARS-CoV-2 Neutralizing Antibody ELISA Kit and Rapid Detection test and the comparator PRNT assay. [Day one]
PPA (Sensitivity) between ≥87% with a lower bound of the 95% confidence interval greater than 74.4% NPA (Specificity) ≥ 93% with a lower bound of the 95% confidence interval greater than 87.8%
Secondary Outcome Measures
- Safety endpoint: adverse events [Single study visit]
Number of adverse events related to blood sample testing in tested participants.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
≥ 18 years of age
-
Able and willing to provide written informed consent
-
Previously diagnosed as SARS-CoV-2 positive by any FDA EUA approved assay with a symptom onset date within the previous 30 days and who are willing to provide a nasopharyngeal swab for RT-PCR testing
-
Suspected of previous SARS-CoV-2 infection and willing to provide a nasopharyngeal swab for RT-PCR testing
-
Previously diagnosed as SARS-CoV-2 positive by a FDA EUA approved RT-PCR assay with a symptom onset date greater than 30 days and a known date of PCR sample collection and symptom severity
Exclusion Criteria:
- Any significant medical, psychological, or social condition which in the opinion of the investigator may preclude the subject from participating in the trial
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Mississippi State University | Starkville | Mississippi | United States | 39762 |
| 2 | Joy Internal Medicine | Englewood Cliffs | New Jersey | United States | 07632 |
| 3 | WellNow Urgent Care | Cincinnati | Ohio | United States | 45215 |
| 4 | WellNow Urgent Care | Columbus | Ohio | United States | 43214 |
| 5 | WellNow Urgent Care | Dayton | Ohio | United States | 45424 |
Sponsors and Collaborators
- MiCo BioMed Co., Ltd.
- Syntactx
Investigators
- Study Director: Jay Hahn, PhD, MiCo BioMed
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- MIC-US-2021-001